Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288224 | 0.81 | HSD17B10 (0.57) | MEN1KMT2AALDH1A1PKMCYP1B1 | |
| SCHEMBL2959641 | 0.81 | ALDH1A1 (1.00) | MEN1KMT2AALDH1A1PKMCYP1B1 | |
| SCHEMBL30711693 | 0.81 | ALDH1A1 (1.00) | MEN1KMT2AALDH1A1PKMCYP1B1 | |
| SCHEMBL29263678 | 0.79 | TDP1 (0.56) | MEN1KMT2AALDH1A1PKMCYP1B1 | |
| SCHEMBL31035955 | 0.79 | TDP1 (0.56) | MEN1KMT2AALDH1A1PKMCYP1B1 | |
| SCHEMBL240611 | 0.77 | MEN1 (0.68) | MEN1KMT2AALDH1A1PKMCYP1B1 | |
| SCHEMBL2036042 | 0.75 | ALDH1A1 (0.57) | MEN1KMT2AALDH1A1PKMCYP1B1 | |
| SCHEMBL45682 | 0.75 | KDM4E (0.75) | MEN1KMT2AALDH1A1CYP1B1MAPT | |
| SCHEMBL17293770 | 0.74 | MEN1 (0.64) | MEN1KMT2AALDH1A1PKMCYP1B1 | |
| SCHEMBL29774137 | 0.74 | MEN1 (0.64) | MEN1KMT2AALDH1A1PKMCYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773641-B1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2017-09-27 | — | — | EP | disclosed |
| WO-2017049409-A1 | COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017049409-A1 | COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2017-03-30 | — | — | WO | disclosed |
| US-9481677-B2 | Biaryl ether sulfonamides and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9365578-B2 | — | — | 2016-06-14 | — | — | US | disclosed |
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| EP-2773641-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064984-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-7838533-B2 | Azaindole inhibitors of MTP and ApoB | MERCK PATENT GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-7838533-B2 | Azaindole inhibitors of MTP and ApoB | MERCK PATENT GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| EP-2054408-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | Novartis Ag (CH) | 2009-05-06 | — | — | EP | disclosed |
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
| EP-1771446-B1 | AZAINDOLE INHIBITORS OF MTP AND APOB | MERCK PATENT GMBH (DE) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | MEN1 4841/4885KMT2A 773/4885ALDH1A1 433/4885 |
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | APOB, MTPN, HDLBP | MEN1 4013/4885KMT2A 3937/4885ALDH1A1 3630/4885 |
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | MEN1 4876/4885KMT2A 2098/4885ALDH1A1 451/4885 |
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPV3, TRPV2 | MEN1 4222/4885KMT2A 1370/4885ALDH1A1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.